Log in to your Inderes Free account to see all free content on this page.
Xbrane Biopharma
9.75 SEK
+7.18 %
Less than 1K followers
XBRANE
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+7.18 %
-9.76 %
-71.14 %
-69.78 %
-51.51 %
-56.88 %
-99.02 %
-99.02 %
-97.96 %
Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.
Read moreMarket cap
200.82M SEK
Turnover
967.08K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
20.2.
2026
Annual report '25
5.5.
2026
Interim report Q1'26
5.5.
2026
General meeting '26
All
Webcasts
Press releases
ShowingAll content types
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
Redeye: Xbrane Biopharma (Q3 update) - Headwinds have continued
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
